2006 Biopharma Pharmaceutical manufacturing 
pharmaphorum
DECEMBER 28, 2022
In 2018, over 60% of all new molecular entities came from smaller biopharma firms, compared with just over 30% in 2009. In addition, she worked as head of inspectorate and licensing for the MHRA from 2004-2006. She joined NSF in 2017.
pharmaphorum
AUGUST 4, 2022
In particular, for the pharmaceutical industry, these talent shortages bring about a host of difficult challenges. This is due to the specialist nature of roles and the growth and diversification of biopharma, which requires an increasingly sophisticated and skilled workforce. Training and development. She joined NSF in 2017.
Expert insights. Personalized for you.
109 
Let's personalize your content